Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases

Cited by (336)

Items 201–300 of 336

1. Small-interfering RNA targeting proprotein convertase subtilisin/kexin type 9 might promote fatty liver disease and hepatocellular carcinoma through upregulation of CD36
   Frank Sheng Fan · 2023 · Tumor Biology
2. Corrected and republished from: Metabolic associated liver disease
   Gianni Testino, Rinaldo Pellicano · 2023 · Panminerva Medica
3. Associations of non‐alcoholic fatty liver disease and cirrhosis with liver cancer in European and East Asian populations: A Mendelian randomization study
   Yunyang Deng, Junjie Huang, Martin C. S. Wong · 2023 · Cancer Reports
4. Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study
   Daniel Q. Huang, Sally Tran, Scott Douglas Barnett, Biyao Zou, Yee Hui Yeo, Ramsey C Cheung, Mindie H. Nguyen · 2023 · Hepatology International
5. NASH and HCC Are Driven by Different Signaling Pathways with a Common Regulator
   Wajahat Zafar Mehal · 2019 · Cell Metabolism
6. Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country
   Noor Atika Azit, Shahnorbanun Sahran, Leow Voon Meng, Manisekar Subramaniam, Suryati Mokhtar, Azmawati Mohammed Nawi · 2021 · PLoS ONE
7. Impaired Response to Immunotherapy in Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma?
   M. Kudo · 2021 · Liver Cancer
8. Hepatocellular Carcinoma Surveillance
   Eden Koo, Amit G. Singal · 2023 · Surgical Oncology Clinics of North America
9. Risk factors associated with late hepatocellular carcinoma detection in patients undergoing regular surveillance
   Sangmi Jang, Young‐Joo Jin, Jin‐Woo Lee, Dam Kwon, Jung Hwan Yu · 2023 · Medicine
10. Diagnostic Performance of Abbreviated MRI for HCC Detection in Patients with Non-alcoholic Fatty Liver Disease
    Raghuraman Soundararajan, A.B. Pooja, Pankaj C. Gupta, Ajay Gulati, Naveen Kalra, Shravya Singh, Madhumita Premkumar, Sunil Taneja, Vaneet Jearth, Vishal Sharma et al. · 2023 · Journal of Clinical and Experimental Hepatology
11. The Effect of Non‐Alcoholic Fatty Liver Disease on Weight Loss and Resolution of Obesity‐Related Disorders After Bariatric Surgery
    Thaer S. A. Abdalla, Anastasios D. Giannou, Ahmed S. A. Abdalla, Jakob Robert Izbicki, Anna Duprée, Oliver Mann, Stefan Wolter · 2023 · World Journal of Surgery
12. A preoperative risk score based on early recurrence for estimating outcomes after resection of hepatocellular carcinoma in the non-cirrhotic liver
    Eloy Ruiz, Jorge Honles, Ramiro Fernández, Ana Karla Uribe Rivera, Juan‐Pablo Cerapio, Karina Cancino, Juan Contreras‐Mancilla, Sandro A. Casavilca-Zambrano, Francisco Berrospi, Pascal Pineau et al. · 2024 · HPB
13. Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge
    Justin A. Steggerda, Krishnaraj Mahendraraj, Tsuyoshi Todo, Mazen Noureddin · 2020 · World Journal of Gastroenterology
14. Challenges and barriers in hepatocellular carcinoma (HCC) surveillance for patients with non-alcoholic fatty liver disease (NAFLD)
    Kara Wegermann, Anna Mae Diehl, Cynthia A. Moylan · 2023 · Hepatoma Research
15. Impact of mixed cryoglobulinemia on patients with spontaneous hepatitis C virus clearance: A 13‐year prospective cohort study
    Kuan‐Chieh Lee, Ya‐Ting Cheng, Cheng‐Yu Lin, Chia‐Jung Kuo, Rong‐Nan Chien, Chau‐Ting Yeh, Ming‐Ling Chang · 2019 · European Journal of Clinical Investigation
16. Role of Alcohol in Steatotic Liver Disease: Impact on Patients with Cardiometabolic Risk Factors
    Francisco Capinha, Sofia C. Carvalhana, Helena Cortez‐Pinto · 2025 · Digestive Diseases and Sciences
17. The African Middle East Association of Gastroenterology (AMAGE) clinical practice guidelines for the diagnosis and management of metabolic dysfunction associated fatty liver disease
    Yasser Fouad, Reda Elwakil, Faisal M. Sanai, Olusegun Sylvester Ojo, Sameer Al Awadhi, Ponsiano Ocama, Nadia Abdelaaty Abdelkader, Said A. Al‐Busafi, Yaw Asante Awuku, Samy Zaki et al. · 2026 · Annals of Hepatology
18. The second Mexican consensus on hepatocellular carcinoma. Part I: Epidemiology and diagnosis
    Laura Esthela Cisneros-Garza, M.S. González-Huezo, Carlos Moctezuma‐Velázquez, L. Ladrón de Guevara-Cetina, Mario Vilatobá, Ignacio García-Juárez, R. Alvarado-Reyes, Guillermo Alberto Álvarez-Treviño, Silvia Allende‐Pérez, L. Bornstein-Quevedo et al. · 2022 · Revista de Gastroenterología de México (English Edition)
19. Differentially Expressed Genes in Response to a Squalene-Supplemented Diet Are Accurate Discriminants of Porcine Non-Alcoholic Steatohepatitis
    Roubi Abuobeid, Luis Vicente Herrera-Marcos, Carmen Arnal, Seyed Hesamoddin Bidooki, Javier Sánchez-Marco, Roberto Lasheras, Joaquín Carlos Surra, María Jesús Rodriguez‐Yoldi, Roberto Martínez‐Beamonte, Jesús Osada · 2023 · International Journal of Molecular Sciences
20. A nationwide study on hepatocellular carcinoma
    Bjarki Sigurdsson, Ragna Sigurdardóttir, Margrét Arnardóttir, Sigrún H. Lund, Jon Gunnlaugur Jonasson, Einar Stefan Bjornsson · 2020 · Cancer Epidemiology
21. Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?
    Ju Hyun Shim · 2020 · Clinical and Molecular Hepatology
22. Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review
    Han Ah Lee · 2024 · Ewha Medical Journal
23. Overeating: A Conundrum of Lipid Metabolism and Inflammation in Obesity and Cancer
    Aizhan Surumbayeva, Yedidya Saiman, Igor A. Astsaturov · 2025 · Journal of Cellular Physiology
24. Ultrasonography in surveillance for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease
    Theresa Hydes, Daniel James Cuthbertson, Daniel H. Palmer, Omar Elshaarawy, Philip James Johnson, Rashika Fernando, Timothy Cross · 2023 · Hepatoma Research
25. Persisting challenges in the early detection of hepatocellular carcinoma
    Ashwini Arvind, K. Redmon, Amit G. Singal · 2025 · Expert Review of Anticancer Therapy
26. Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations
    Jacob George, Nicole L. Allard, Stuart Keith Roberts, Leon Anton Adams, Jane Davies, Behzad Hajarizadeh, Jennifer H MacLachlan, Suzanne E. Mahady, Rosalie Altus, Cath Brown et al. · 2025 · The Medical Journal of Australia
27. Acute Viral Hepatitis
    Jay H. Lefkowitch · 2020 · Elsevier eBooks
28. Accuracy of attenuation imaging in the assessment of pediatric hepatic steatosis: correlation with the controlled attenuation parameter
    Pyeong Hwa Kim, Young Ah Cho, Hee Mang Yoon, Boram Bak, Jin Seong Lee, Ah Young Jung, Seak Hee Oh, Kyung Mo Kim · 2022 · ULTRASONOGRAPHY
29. Stéatose hépatique non alcoolique : diagnostic et traitement en 2022
    Nikoletta Maria Tagkou, Nicolas Goossens · 2023 · Schweizer Gastroenterologie
30. The Growing Landscape of NAFLD-Associated Hepatocellular Carcinoma and Its Impact in Surveillance
    Mariana Verdelho Machado · 2023 · GE Portuguese Journal of Gastroenterology
31. Immunotherapy as a Complement to Surgical Management of Hepatocellular Carcinoma
    Susan J. Kim, Kaelyn C. Cummins, Allan Tsung · 2024 · Cancers
32. Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal nationwide study
    Rongtao Lai, Scott Douglas Barnett, Xinrong Zhang, Leslie Yeeman Kam, Ramsey C Cheung, Qing Xie, Mindie H. Nguyen · 2024 · PLoS Medicine
33. Chronological changes in etiology, pathological and imaging findings in primary liver cancer from 2001 to 2020
    Junya Tsuzaki, Akihisa Ueno, Yohei Masugi, Masashi Tamura, Seiichiro Yamazaki, Kosuke Matsuda, Yutaka Kurebayashi, Hiroto Sakai, Yoichi Yokoyama, Abe Yuta et al. · 2024 · Japanese Journal of Clinical Oncology
34. II Consenso Mexicano de Carcinoma Hepatocelular. Parte I: Epidemiología y diagnóstico
    Laura Esthela Cisneros-Garza, M.S. González-Huezo, Carlos Moctezuma‐Velázquez, L. Ladrón de Guevara-Cetina, Mario Vilatobá, Ignacio García-Juárez, R. Alvarado-Reyes, Guillermo Alberto Álvarez-Treviño, Silvia Allende‐Pérez, L. Bornstein-Quevedo et al. · 2022 · Revista de Gastroenterología de México
35. Progression of liver disease and associated risk of hepatocellular carcinoma
    Edoardo Poli, Eléonora De Martin · 2024 · Hepatoma Research
36. Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response
    Camilo Julio Llamoza-Torres, María Fuentes-Pardo, Bruno Ramos‐Molina · 2024 · Metabolism and Target Organ Damage
37. PLD2 is a marker for MASLD-HCC with early-stage fibrosis: revealed by lipidomic and gene expression analysis
    Jihan Sun, Fatima Dahboul, Estelle Pujos‐Guillot, Mélanie Pétéra, Emeline Chu‐Van, Benoît Colsch, Delphine Weil, Vincent Di Martino, Aïcha Demidem, Armand Abergel · 2025 · Metabolomics
38. Linking the Planetary Health Diet Index to sarcopenia: the mediating effect of the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR)
    Huan Chen, Zhao Wang, Changsin Lee, Rongcan Liu, Junlong Song, Jun‐Sheng Zhang, Ning Du, Chan Kang · 2025 · Frontiers in Nutrition
39. Primary-like Human Hepatocytes Genetically Engineered to Obtain Proliferation Competence as a Capable Application for Energy Metabolism Experiments in In Vitro Oncologic Liver Models
    Andrea Scheffschick, Jonas Babel, Sebastian Sperling, Julia Nerusch, Natalie Herzog, Daniel Seehofer, Georg Damm · 2022 · Biology
40. A multi-strategy liposome targeting hepatocellular carcinoma cells and stem cells enhances the chemotherapy effect of doxorubicin in hepatocellular carcinoma
    Liang Kong, Guoyuan Sui, Ruibo Guo, Huimin Cao, Yang Yu, Yang Liu, Yuan Cao, Xing Ju, Yuhui Yan, Yu-han Ao et al. · 2023 · Journal of Drug Delivery Science and Technology
41. Diabetes is associated with increased risk of hepatocellular carcinoma in non-alcoholic steatohepatitis with cirrhosis—implications for surveillance and future pharmacotherapy
    Michael Patrick Johnston, Janisha Patel, Christopher D. Byrne · 2020 · HepatoBiliary Surgery and Nutrition
42. The crystallisation of Poly (aryl ether etherketone) (PEEK) and its carbon fibre composites
    Andrew James Herrod-Taylor · 2011 · UPT. Syiah Kuala University Library (Syiah Kuala University)
43. Characterisation of non-cirrhotic MAFLD-related hepatocellular carcinoma: a retrospective cohort study
    Shadi Zerehpooshnesfchi, Fatema Safri, Ziyan Pan, Romario Nguyen, Lawrence Yuen, Vincent Wai-To Lam, Christopher Bahdah Nahm, Tony Pang, Golo Ahlenstiel, Jacob George et al. · 2025 · Therapeutic Advances in Chronic Disease
44. The correlation between novel antidiabetic agents utilization and hepatocellular carcinoma incidence in type 2 diabetes patients: a network meta-analysis
    Junjie Lin, Tianshu Ren, Qingchun Zhao, Qiang Tong, Jiahui Liu, Kang Ye, Yuan Yuan · 2025 · European Journal of Clinical Pharmacology
45. Mechanisms of innate immune cells in Metabolic dysfunction-associated steatotic liver disease
    Yao Yao, Qiong Wu, Bin Fan, Xin Peng, Mingwei Sheng, Fengmei Wang · 2025 · Frontiers in Immunology
46. Protective effect and mechanisms of puerarin in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis of animal studies
    Xiangyun Zou, Yucheng Yang, Xuehan Liu, Wenying Qi, Xiaobin Zao, Xiaoke Li, Yongan Ye · 2025 · Pharmacological Research
47. HCC Is the Predominant Liver-Related Event in MASLD: 2-Step Non-Invasive Algorithms to Stratify Risk in Non-Cirrhotic Patients
    Mădălina-Gabriela Țâru, Bernardo Stefanini, Maria Boe, Roberta Capelli, Rusi Chen, Chiara Abbati, Ernestina Santangeli, Agnese Salamone, Francesca Girolami, Francesco Tovoli et al. · 2026 · Journal of Hepatocellular Carcinoma
48. Role of noninvasive tests on the prediction of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without cirrhosis: a systematic review and meta-analysis of aggregate and individual patient data
    Nanicha Siriwong, Supachaya Sriphoosanaphan, Pakanat Decharatanachart, Tanat Yongpisarn, Stephen John Kerr, Sombat Treeprasertsuk, Thodsawit Tiyarattanachai, Terapap Apiparakoon, Hannes Hagström, Camilla Akbari et al. · 2025 · European Journal of Gastroenterology & Hepatology
49. Possible Role of Platelets in the Development and Progression of Non-Alcoholic Fatty Liver Disease
    Anna F. Sheptulina, Ekaterina O. Liusina, Olga A. Zlobovskaya, Anton R. Kiselev, Oksana M. Drapkina · 2025 · Frontiers in Bioscience-Landmark
50. Fatty Liver Index Dynamics as a Predictor of Hepatocellular Carcinoma in Patients with Type 2 Diabetes Mellitus and Non-Cirrhotic Livers
    Eun-Hee Cho, Min Gu Kang, Chang Hun Lee, Shinyoung Oh, Chen Shen, Ha Ram Oh, Young Ran Park, Hyun Jung Lee, Jong Seung Kim, Ji Hyun Park · 2025 · Endocrinology and Metabolism
51. Investigation and Distinction of Energy Metabolism in Proliferating Hepatocytes and Hepatocellular Carcinoma Cells
    Nerusch, Julia, Schicht, Gerda, Herzog, Natalie, Küpper, Jan-Heiner, Seehofer, Daniel, Damm, Georg · 2025 · Cells
52. Nonalcoholic liver disease: review with a focus on risks of progression
    Daria A. Teplyuk, M. Ch. Semenistaya, S. M. Sorokoletov, Leonid Borisovich Lazebnik, Chavdar S Pavlov · 2021 · Экспериментальная и клиническая гастроэнтерология
53. Nonalcoholic fatty liver disease and health outcomes: An umbrella review of systematic reviews and meta-analyses
    Lixian Zhong, Chutian Wu, Yuting Li, Qiuting Zeng, Leizhen Lai, Sisi Chen, Shaohui Tang · 2022 · Therapeutic Advances in Chronic Disease
54. Shared Genes and Molecular Mechanisms between Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma Established by WGCNA Analysis
    Juan He, Xin Zhang, Xi Chen, Zongyao Xu, Xiaoqi Chen, Jiangyan Xu · 2023 · Global Medical Genetics
55. Inhibition of plasminogen suppresses fibrosis and macrophage foaming in a nonalcoholic steatohepatitis mouse model
    Yuki Tomonari, Takayuki Iwaki, Tomohiro Arakawa, Kazuo Umemura · 2022 · Fundamental and Clinical Pharmacology
56. Can liver stiffness measurement accurately predict disease progression and clinical outcome in patients with metabolic dysfunction-associated steatotic liver disease and bridging fibrosis or cirrhosis?
    Diederick J. van Doorn, Adriaan Georgius Holleboom, Robert Bart Takkenberg, Joanne Verheij, Marten Alexander Lantinga · 2023 · HepatoBiliary Surgery and Nutrition
57. Statin Monotherapy Not Inferior to Aspirin or Combined Aspirin and Statins Reducing the Incidences of Cirrhosis, HCC, and Mortality in MAFLD/MASH Patients: A Population Cohort Study
    C H Lee, Yu-Han Huang, Tzu-Ju Hsu, Tzung‐Hai Yen, Sen‐Yung Hsieh · 2024 · International Journal of General Medicine
58. Hepatocellular Carcinoma Among Patients With Metabolic Dysfunction Associated Steatotic Liver Disease
    Obaid Shakil Shaikh, Peng Yan, Adeel Ajwad Butt · 2025 · Gastro Hep Advances
59. Estrogen inhibits hepatocellular carcinoma progression dependent on HOXA11-AS/HOXA11
    Pincheng Zhou, Fengze Sun, Peixu Lin, Yan Yan, Jiayao Liu, Yang Zhou, Ting He, Pengcheng Liu, Jie Wang, Huanhuan Sun et al. · 2025 · Translational Oncology
60. Critical analysis of the liver cancer policies and programs in China: implications for international liver cancer control
    Xianwen Chen, Junnan Shi, Yan Xue, Yunfeng Lai, Menghuan Song, Carolina Oi Lam Ung, Hao Hu · 2025 · Global Health Research and Policy
61. Fecal Microbiota and Bile Acid Profiles in Early-Stage Hepatocellular Carcinoma: A Matched Case-Control Study
    Yael R. Nobel, Heekuk Park, Alice M. Tillman, Dwayne Seeram, Dalia H. Moallem, Anna Intara, Renu Nandakumar, Medini K. Annavajhala, Angela Gomez‐Simmonds, Elizabeth C. Verna et al. · 2025 · Clinical and Translational Gastroenterology
62. Performance of GAAD and GALAD Biomarker Panels for HCC Detection in Patients with MASLD or ALD Cirrhosis
    Mohammad Jarrah, Sneha Deodhar, Lisa Quirk, Mohammed Al-Hasan, Ashish Sharma, Guruveer S. Bhamra, Julia Terrell, Fasiha Kanwal, Yujin Hoshida, Nicole E. Rich et al. · 2025 · Cancers
63. Multi omics analysis reveals senescence associated genes in metabolic dysfunction associated steatohepatitis related liver cancer and their functional validation
    Shixun Lin, Yumeng Teng, Qiulin Wu, Zhiqiang Wang, Xiaoyan Feng, Jingquan Huang, Yongchao Zeng, Zhao Fan, Yihe Yan · 2026 · International Journal of Biological Macromolecules
64. Gut Microbiome and Nonalcoholic Fatty Liver Disease (NAFLD)
    Yinji Liang, Shuang Zhou, Xinhe Chen, Lebing Yu, Dongling Zhang, Chenli Lin · 2021 · Gastroenterology Nursing
65. EFFECT OF INTERMITTENT FASTING ON CARBOHYDRATE, LIPID AND ULTRASONOGRAPHIC PARAMETERS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND PREDIABETES
    Ksenia I. Chubirko, Mykhaylo M. Hechko, Taras I. Griadil, Ivan V. Chopey · 2023 · Wiadomości Lekarskie
66. Hepatocellular Carcinoma from a Hepatologist's Perspective
    Giovanni A. Roldan, Jacquelin Blomker, Elizabeth S. Aby · 2023 · Seminars in Interventional Radiology
67. Proteome-wide Mendelian randomization identifies potential therapeutic targets for nonalcoholic fatty liver diseases
    Junhang Li, Xiang Ma, Cuihua Yin · 2024 · Scientific Reports
68. Elongation factor 1A1 inhibition elicits changes in lipid droplet size, the bulk transcriptome, and cell type-associated gene expression in MASLD mouse liver
    Rachel B. Wilson, Yun Jin Chen, Richard Zhang, Siddhant Maini, Tallulah S. Andrews, Rennian Wang, Nica M. Borradaile · 2024 · American Journal of Physiology-Gastrointestinal and Liver Physiology
69. SOX9 Overexpression Ameliorates Metabolic Dysfunction-associated Steatohepatitis Through Activation of the AMPK Pathway
    Juan Deng, Kai Ding, Shuqing Liu, Fei Chen, Ru Huang, Bonan Xu, Xin Zhang, Wei‐Fen Xie · 2024 · Journal of Clinical and Translational Hepatology
70. Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of hepatocellular carcinoma: A systematic review and meta-analysis
    Kunlin Chen, Ming Jun Yang, Guangjun Li, Wentao Wang · 2025 · PLoS ONE
71. The potential for primary and secondary prevention of liver cancer death in Australians with alcohol-related liver disease or metabolic-associated steatotic liver disease: A modelling study
    Joachim Worthington, Emily He, Georgia Carney, Paul B. Grogan, Megan Varlow, Karen Canfell, Eleonora Feletto · 2025 · Public Health
72. Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Diagnosis— AJR Expert Panel Narrative Review
    Lingling Li, Marco Dioguardi Burgio, David T. Fetzer, Giovanna Ferraioli, Andrej P. Lyshchik, Maria Franca Meloni, Vasileios D. Rafailidis, Paul Singh Sidhu, Valérie Vilgrain, Stephanie R. Wilson et al. · 2025 · American Journal of Roentgenology
73. Hepatocellular carcinoma
    Lampros Chrysavgis, Εvangelos Cholongitas · 2025 · Elsevier eBooks
74. Diabetes and hepatocellular carcinoma risks in patients with nonalcoholic steatohepatitis related cirrhosis
    Chien‐Hsieh Chiang, Kuo‐Chin Huang · 2020 · HepatoBiliary Surgery and Nutrition
75. Editorial: screening for hepatocellular carcinoma in NAFLD —towards abbreviated MRI alternative in patients with obesity?
    Fanny Lebossé, Cyrielle Caussy · 2022 · Alimentary Pharmacology & Therapeutics
76. Novel Therapies for Nonalcoholic Steatohepatitis (NASH) and Cardiovascular Risk Reduction
    Tarun Biswas, Angelica Lehker, Debabrata Mukherjee · 2024 · Cardiovascular & Haematological Disorders - Drug Targets
77. Reducing complications of metabolic dysfunction–associated steatotic liver disease
    Naohiro Wada, Michihiro Iwaki, Takashi Kobayashi, Atsushi Nakajima, Masato Yoneda · 2025 · Expert Review of Gastroenterology & Hepatology
78. Bibliometric and visualized analysis of mitophagy in liver cancer from 1998 to 2024
    Shanshan Gong, Yuchang Fei · 2025 · Discover Oncology
79. Can AI Guide the Decision to Transplant or Resect for Hepatocellular Carcinoma?
    Varvara A. Kirchner, Timothy L. Pruett · 2025 · JAMA Network Open
80. CircSMEK1 Suppresses HCC via the hnRNPK‐IGF2‐AKT Axis: A Diagnostic Biomarker and Therapeutic Target
    Peilan Guo, Xiaomeng Jia, Shenghong Wang, Xinyu Li, Yajing Liu, Lisen Lin, Zhengkun Wang, Fujun Liu, Sławomir Wołczyński, Nafis Ahmed Rahman et al. · 2025 · Advanced Science
81. Recent advances in therapeutic and surgical approaches in locally advanced HCC: downstaging and neoadjuvant therapy
    Anudari Zorigtbaatar, Kenan Moral, Gonzalo Sapisochín, Gökhan Kabaçam, Nazia Selzner, Parissa Tabrizian, Rebecca Marino · 2026 · International Journal of Surgery
82. Current management of MASLD in type 2 diabetes
    Valeria Michelle Fernández‐Garibay, Vianney Sarabia-Chao, Norberto Carlos Chávez-Tapia · 2026 · HORMONES
83. The future of blood-based biomarkers in liver cancer
    Amit G. Singal, Anna Lena Saborowski, Neehar D. Parikh, Jesus M. Banales · 2026 · Journal of Hepatology
84. Molecular Pathophysiology of Hepatocellular Carcinoma: From Metabolic Inflammation to Therapeutic Targets
    Sara M. Azzam, Alexandra J Straus, Can E. Senkal, Devanand Sarkar · 2026 · Cancers
85. The Impact of HCC Surveillance on Tumor Features and Receipt of Curative Therapy: A Focus on Chronic Hepatitis B and MASLD
    Shao-Li Huang, Hsi‐An Chen, Chun‐Hsun Liao, Shih-Chi Hu, Shang‐Chin Huang, Chun‐Jen Liu, Tung‐Hung Su, Jia‐Horng Kao · 2026 · Journal of Gastroenterology and Hepatology
86. Interventional Management of Portal Hypertension in Cancer Patients
    Max Kabolowsky, Lyndsey Nguyen, Brett E. Fortune, Ernesto Santos, Sirish A. Kishore, Juan C. Camacho · 2022 · Current Oncology Reports
87. Surgical treatment of obesity for NAFLD
    Donald Goens, Crystal N. Johnson-Mann, Amir Zarrinpar, Heather M. Patton · 2024 · Elsevier eBooks
88. Natural history of nonalcoholic fatty liver disease
    Dominic Crocombe, Emmanuel A. Tsochatzis · 2024 · Elsevier eBooks
89. Research Progress on Multidisciplinary Intervention for Metabolic Dysfunction-Associated Steatotic Liver Disease and Related Liver Cancer
    Yu Zhang, Chao Xu · 2024 · Journal of Biosciences and Medicines
90. Role of Tissue Biopsy in Drug Development for Nonalcoholic Fatty Liver Disease and Other Metabolic Disorders
    Andrew J. Krentz, Pierre Bédossa · 2019 · Springer eBooks
91. Optimizing patients with non-alcoholic fatty liver disease pre-transplant
    Amine Benmassaoud, Marc Deschênes, Tianyan Chen, Peter Ghali, Giada Sebastiani · 2020 · Canadian Liver Journal
92. Hepatocellular Carcinoma: Diagnosis and Surveillance
    Aditya P. Kale · 2021 · IntechOpen eBooks
93. Fettleber und Cholezystopathie
    Tanja Kaltenbach, Wolfgang Kratzer · 2022 · Springer eBooks
94. The Role of Senescence in NASH-Related HCC
    Lampros Chrysavgis, Grigorios Papadopoulos, Antonios Chatzigeorgiou · 2022 · Interdisciplinary cancer research
95. Editorial: hepatocellular carcinoma in non‐cirrhotic NASH —a troubling reality
    Marie Boyle, Quentin Mark Anstee · 2018 · Alimentary Pharmacology & Therapeutics
96. AATF-mediated Liver Damage and Inflammation to Cancer: Therapeutic Intervention by Curcumin in Experimental MASH-HCC
    Akshatha N. Srinivas, Diwakar Suresh, Saravana Babu Chidambaram, Prasanna K. Santhekadur, Divya P. Kumar · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
97. The evaluation of complications and mortality in non-alcoholic steatohepatitis-related cirrhosis
    Sezgin Vatansever, Zehra Betül Paköz · 2018 · Marmara medical journal
98. Editorial comment on hepatocellular carcinoma in the noncirrhotic liver: Clinical characteristics and results in Veracruz, Mexico
    Carlos Moctezuma‐Velázquez · 2021 · Revista de Gastroenterología de México (English Edition)
99. A Correlation Study Between Non-alcoholic Fatty Liver Disease and Serum Triglyceride Level After an Oral Fat Tolerance Test
    Xiaoyu Hou, Yunpeng Guan, Yong Tang, An Song, Jiajun Zhao, Luping Ren, Shuchun Chen, Limin Wei, Huijuan Ma, Guangyao Song · 2021 · Research Square
100. Gut-Hepatic Relationship: From Disorders of the Gut Microbiota to Hepatocellular Carcinoma
     Ilkham Torobekovich Murkamilov · 2021 · American Journal of Biomedical Science & Research